^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Breast Cancer
    Drug:Halaven (eribulin mesylate) (Microtubule inhibitor, CBP inhibitor, β-catenin inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    10/19/2016
    Excerpt:
    HALAVEN is a microtubule inhibitor indicated for the treatment of patients with...Metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    Eisai Press Release
    Title:

    HALAVEN RECEIVES APPROVAL IN JAPAN FOR THE TREATMENT OF INOPERABLE AND RECURRENT BREAST CANCER

    Published date:
    04/22/2011
    Excerpt:
    Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, “Eisai”) announced today that it has received approval to market its novel anticancer Halaven Injection 1mg (eribulin mesylate) in Japan for the treatment of inoperable and recurrent breast cancer.
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    03/17/2011
    Excerpt:
    Halaven monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer...